Soluble urokinase plasminogen activator receptor in blood transfusion components

Summary.  Post‐transfusion infectious complications associated with allogeneic blood components may depend on storage time and may be related to extracellular accumulation of bioactive substances during storage. The glycoprotein, soluble urokinase plasminogen activator receptor (suPAR), which is located in specific granules of neutrophils, plays a role in inflammation and remodelling of the extracellular matrix. Using enzyme‐linked immunosorbent assay, suPAR was determined in serum, plasma and blood cell lysates. In addition, suPAR was measured in whole blood (WB), buffy‐coat‐depleted saline‐adenine‐glucose‐mannitol (SAGM) blood, platelet‐rich plasma (PRP) and buffy‐coat‐derived platelet (BCP) pools with and without pre‐storage leucofiltration, and in non‐filtered WB, SAGM blood and platelet concentrates prepared using apheresis (APC) at different time points during storage. Mean suPAR concentration was significantly higher in cell lysates, compared to that in a corresponding serum (P = 0·007) and in plasma samples (P = 0·004). Mean suPAR levels in WB, BCP and SAGM were significantly reduced using leucofiltration (WB: 3·4 versus 2·0 ng mL−1; BCP: 1·6 versus 1·1 ng mL−1; SAGM: 2·8 versus 0·19 ng mL−1), whereas no difference was observed in PRP. In non‐filtered WB, SAGM and APC, extracellular suPAR accumulated significantly in a storage‐time‐dependent manner (WB: P < 0·01; SAGM: P < 0·001; APC: P < 0·001). The present study demonstrates that cell lysates contain significantly more suPAR, compared to both serum and plasma. This can be explained by the release of suPAR from intracellular granules during cell lysis. The amount of suPAR is significantly increased during storage of blood transfusion components, an accumulation that is reduced using pre‐storage leucofiltration.

[1]  T. Mynster Blood transfusion-induced immunomodulation--is storage time important? , 2003, Danish medical bulletin.

[2]  N. Brünner,et al.  Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  S. Rabbani,et al.  Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. , 2002, Cancer research.

[4]  N. Brünner,et al.  Soluble Urokinase Plasminogen Activator Receptor Measurements: Influence of Sample Handling , 2001, The International journal of biological markers.

[5]  U. Weidle,et al.  Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor. , 2001, The Biochemical journal.

[6]  H. Nielsen,et al.  Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases. , 2001, Gynecologic oncology.

[7]  E. Rondeau Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia. , 2001, Kidney international.

[8]  N. Brünner,et al.  Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients. , 2001, European journal of cancer.

[9]  E. Vamvakas,et al.  Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? , 2001, Blood.

[10]  L. Van De Watering,et al.  Perioperative blood transfusions, with or without allogeneic leucocytes, relate to survival, not to cancer recurrence , 2001, The British journal of surgery.

[11]  H. Ullum,et al.  Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. , 2000, Blood.

[12]  Maciej Pysz Blood transfusions in breast cancer patients undergoing mastectomy: Possible importance of timing , 2000, Journal of surgical oncology.

[13]  I. Christensen,et al.  Effects of the combination of blood transfusion and postoperative infectious complications on prognosis after surgery for colorectal cancer , 2000, The British journal of surgery.

[14]  R. McLeod,et al.  Allogeneic Red Blood Cell Transfusion Is an Independent Risk Factor for the Development of Postoperative Bacterial Infection , 2000, Vox Sanguinis.

[15]  M. Mann,et al.  A Urokinase Receptor-associated Protein with Specific Collagen Binding Properties* , 2000, The Journal of Biological Chemistry.

[16]  N. Brünner,et al.  Soluble vascular endothelial growth factor in various blood transfusion components , 1999, Transfusion.

[17]  D. Rifkin,et al.  Cellular glycosylphosphatidylinositol‐specific phospholipase D regulates urokinase receptor shedding and cell surface expression , 1999, Journal of cellular physiology.

[18]  H. Nielsen,et al.  Reduction of bioactive substances in stored donor blood: prestorage versus bedside leucofiltration , 1999, European journal of haematology.

[19]  H. Nielsen,et al.  Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. , 1999, Journal of the National Cancer Institute.

[20]  F. Blasi The urokinase receptor. A cell surface, regulated chemokine , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[21]  H. Nielsen,et al.  Bioactive substances in buffy‐coat‐derived platelet pools stored in platelet‐additive solutions , 1998, British journal of haematology.

[22]  H. Nielsen Clinical Impact of Bioactive Substances in Blood Components: Implications for Leukocyte Filtration , 1998, Transfusion Medicine and Hemotherapy.

[23]  R. Stephens,et al.  The urokinase receptor , 1998 .

[24]  N. Brünner,et al.  The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. , 1998, Cancer research.

[25]  R. Medcalf,et al.  The urokinase-type-plasminogen-activator receptor (CD87) is a pleiotropic molecule. , 1998, European journal of biochemistry.

[26]  Michael V. Doyle,et al.  Regulation of Integrin Function by the Urokinase Receptor , 1996, Science.

[27]  H. Nielsen,et al.  Leucocyte and platelet derived bioactive substances in stored standard platelet concentrates , 1996, European journal of haematology.

[28]  F. Blasi,et al.  Proteolytic cleavage of the urokinase receptor substitutes for the agonist‐induced chemotactic effect. , 1996, The EMBO journal.

[29]  N. Brünner,et al.  The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion , 1995 .

[30]  H. J. Nielsen,et al.  Detrimental effects of perioperative blood transfusion , 1995, The British journal of surgery.

[31]  M. Gyetko,et al.  The urokinase receptor is required for human monocyte chemotaxis in vitro. , 1994, The Journal of clinical investigation.

[32]  N. E. Hansen,et al.  The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils. , 1994, Blood.

[33]  L. Lund,et al.  Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. , 1992, The Journal of biological chemistry.

[34]  N. E. Hansen,et al.  A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria. , 1992, European journal of biochemistry.

[35]  P. Walsh,et al.  Prostate cancer recurrence in radical surgery patients receiving autologous or homologous blood , 1992, Transfusion.

[36]  M. Ploug,et al.  Cell‐induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2‐terminal domain of the urokinase receptor , 1991, FEBS letters.

[37]  D. Fry,et al.  Breast cancer survival and perioperative blood transfusion. , 1989, Surgery.

[38]  W. Russell,et al.  Histamine levels in stored human blood , 1984, Transfusion.

[39]  T. van der Poll,et al.  Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia. , 2001, Kidney international.

[40]  K. Preissner,et al.  Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. , 1998, Blood.

[41]  F. Blasi The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion , 1994 .

[42]  L. Kołodziejski,et al.  Blood transfusion and survival after surgery for stage I and II breast cancer. , 1993, Neoplasma.

[43]  W. Ross Blood transfusions and prognosis in colorectal cancer. , 1993, The New England journal of medicine.

[44]  K. Danø,et al.  Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.